COLINZ LABORATORIES LTD. (COLINZ) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of COLINZ LABORATORIES LTD. ₹34.72, price ₹73.50, upside -52.8%, quality 66 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch COLINZ LABORATORIES LTD. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
60‑month range ₹15.20 – ₹85.92 · fair‑value band ₹26.04 – ₹44.12 · the ₹73.50 price screens above the ₹34.72 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.
Follow COLINZ LABORATORIES in your weekly email
Every Wednesday you see whether COLINZ LABORATORIES is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
COLINZ LABORATORIES LTD. (COLINZ) currently trades at ₹73.50, while our model-based Fair Value estimate is ₹34.72, 52.8% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of ₹73.23 per share, and 4 of the 21 models we run sit above the ₹73.50 price.
Bear case: the Earnings-Based group reads lowest at ₹11.39, and 17 of the 21 models stay below the price. Evidence for this calculation is low.
Scenario range: ₹26.04 (bear) to ₹44.12 (bull), the price of ₹73.50 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 66/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
COLINZ LABORATORIES LTD. reported revenue of ₹61.4M in FY2025 versus ₹69.7M in FY2021, a compound −3.2%/yr. Reported net income was ₹5.1M in FY2025, compounding +11.0%/yr from FY2021.
Key figures
Market cap ₹185M (≈ $1.9M) · P/E ratio 6.6 · P/S ratio 0.56 · EPS (TTM) ₹11.10 · Net margin 8.4% · Return on equity 5.3% · Return on assets (EBIT) 3.5% · Operating margin 1.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 14% below its 52-week high and 85% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −10% fair-value upside, at −53%, COLINZ screens richer than that median.
Fair Value models
Bear ₹26.04Fair Value ₹34.72Bull ₹44.12
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (₹8.39 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−6.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.1%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.0%
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+35.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+35.1%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.35.1% vs 17.8%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.2% → 4%
Start year 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−10.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about −13.7% a year for the price.
Compare COLINZ LABORATORIES LTD. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Drug Manufacturers - Major” was too small, so the broader sector is used.)Health Care · 2315 stocks
Beats the sector median on 5/12 measures
A mixed picture versus its sector peers.
Valuation
Quality Score66 · Top 25%
Fair Value upside−52.8% · Below median
Profitability
Return on equity (TTM)5.3% · Above median
Return on assets1.3% · Below median
Net margin (TTM)48.1% · Top 25%
Operating margin (TTM)1.9% · Below median
Growth and dividend
Revenue growth−20.8% · Bottom 25%
Valuation Multiplesvs Health Care median · lower = cheaper
P/E (TTM)6.6× · Cheapest 25%
P/B1.84× · Pricier than median
P/S (TTM)3.19× · Pricier than median
P/FCF7.3× · Cheapest 25%
EV/EBITDA52.4× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 7
FUTURE (revenue growth)0· sector 26
PAST (return on equity)21· sector 16
HEALTH (low debt)0· sector 96
DIVIDEND (yield)0· sector 33
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is COLINZ LABORATORIES LTD. (COLINZ) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of ₹34.72 versus a price of ₹73.50, about −53% upside (overvalued).
What is the fair value of COLINZ?
Our model-based fair value for COLINZ LABORATORIES LTD. is ₹34.72 (as of Sep 27, 2026), built from audited fundamentals. The current price: ₹73.50.
What is the quality score of COLINZ?
COLINZ LABORATORIES LTD. has a Quality Score of 66/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for COLINZ LABORATORIES LTD. (COLINZ)?
Our model-based price target is the fair value of ₹34.72 (as of Sep 27, 2026) from 21 valuation models. Cautious scenario ₹26.04, optimistic scenario ₹44.12. It is a calculation from audited fundamentals, not an analyst target.
What is the COLINZ LABORATORIES LTD. stock forecast for 2026?
Our models put fair value at ₹34.72, about −53% upside versus a price of ₹73.50 (overvalued). Cautious scenario ₹26.04, optimistic scenario ₹44.12. The calculation is refreshed regularly with new filings.
What is the revenue of COLINZ LABORATORIES LTD. (COLINZ)?
COLINZ LABORATORIES LTD. reported trailing-twelve-month revenue of about ₹58.1M (latest available figure, as of Sep 27, 2026).
What growth is priced into COLINZ LABORATORIES LTD. (COLINZ)?
For today's price to be fair in a discounted-cash-flow model, COLINZ LABORATORIES LTD. would have to grow free cash flow by -10.2 % per year for five years (discount rate 12.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -0.1 % per year. As of Sep 27, 2026.
What discount rate (WACC) does the fair value of COLINZ use?
Our models discount COLINZ LABORATORIES LTD. at 12.4 %: a base by market capitalisation (nano), country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For COLINZ LABORATORIES LTD. that is -10.2 % per year a year over ten years, using the same discount rate (12.4 %) and the same formula as our fair value.
How much growth has COLINZ LABORATORIES LTD. (COLINZ) delivered so far?
Over the past 5 years revenue at COLINZ LABORATORIES LTD. grew -0.1 % a year. The price currently implies -10.2 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
What is the free cash flow yield of COLINZ LABORATORIES LTD. (COLINZ)?
The free-cash-flow yield on the price is 13.72 %: that much free cash flow COLINZ LABORATORIES LTD. produces per unit of market value. When it exceeds the discount rate of our models (12.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of COLINZ LABORATORIES LTD. (COLINZ)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For COLINZ LABORATORIES LTD. it is ₹34.72 per share (as of Sep 27, 2026), against a price of ₹73.50. It is the blended result of 21 valuation models (cash flow, earnings, asset, dividend).
Is COLINZ LABORATORIES LTD. stock overvalued or undervalued in 2026?
As of Sep 27, 2026, COLINZ trades above its calculated fair value: price ₹73.50, fair value ₹34.72, a gap of about −53% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of COLINZ?
No. The price is what the market pays today (₹73.50); the fair value is what the company's own numbers justify (₹34.72). For COLINZ LABORATORIES LTD. the two are ₹38.78 per share apart. That gap is exactly why we show both numbers side by side.
How much is COLINZ LABORATORIES LTD. worth?
The market values COLINZ LABORATORIES LTD. at about ₹185M (market capitalisation, as of Sep 27, 2026). Per share that is ₹73.50; our models calculate a fair value of ₹34.72 per share.
What do the bullish and bearish scenarios say about COLINZ?
Our models span a range for COLINZ LABORATORIES LTD.: cautious scenario ₹26.04, base ₹34.72, optimistic ₹44.12 per share (as of Sep 27, 2026, price ₹73.50). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of COLINZ?
COLINZ LABORATORIES LTD. trades at a price-to-earnings ratio of 6.6 (as of Sep 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹34.72 is built from several models across several years. Other multiples: P/B 1.8, P/S 3.2, EV/EBITDA 52.4.
How solid is the balance sheet of COLINZ LABORATORIES LTD. (COLINZ)?
Balance-sheet figures for COLINZ LABORATORIES LTD. (as of Sep 27, 2026): return on equity 5.3%. They feed the Quality Score of 66/100, which measures business quality independently of the share price.
How far is COLINZ from its 52-week high?
COLINZ LABORATORIES LTD. trades at ₹73.50, about 14% below its 52-week high of ₹85.92 and 85% above the low of ₹39.75 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹34.72 is for.
Which stocks are comparable to COLINZ LABORATORIES LTD.?
From the same area (Healthcare) we also value Makers Laboratories Limited, Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is COLINZ LABORATORIES LTD. stock attractive at the current price?
The data as of Sep 27, 2026: price ₹73.50, calculated fair value ₹34.72 (−53%), Quality Score 66/100, from 21 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of COLINZ calculated?
We run COLINZ LABORATORIES LTD. through 21 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹34.72, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. COLINZ LABORATORIES LTD. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of COLINZ LABORATORIES LTD. (COLINZ)?
The closing price on Oct 1, 2026 was ₹73.50. Our model-based fair value is ₹34.72, about −53% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with COLINZ LABORATORIES LTD. right now?
The price sits above even our optimistic bull case (₹44.12). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (66/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of COLINZ LABORATORIES LTD.
How large is the market capitalisation of COLINZ LABORATORIES LTD. (COLINZ)?
The market capitalisation of COLINZ LABORATORIES LTD. is ₹185M (≈ $1.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of COLINZ LABORATORIES LTD. (COLINZ)?
The price-to-sales ratio of COLINZ LABORATORIES LTD. is 0.56 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of COLINZ LABORATORIES LTD. (COLINZ)?
Earnings per share at COLINZ LABORATORIES LTD. are ₹11.10 (price ÷ EPS = P/E 6.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of COLINZ LABORATORIES LTD. (COLINZ)?
The net margin of COLINZ LABORATORIES LTD. is 8.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of COLINZ LABORATORIES LTD. (COLINZ)?
The return on equity (ROE) of COLINZ LABORATORIES LTD. is 5.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of COLINZ LABORATORIES LTD. (COLINZ)?
On an EBIT basis the return on assets of COLINZ LABORATORIES LTD. is 3.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of COLINZ LABORATORIES LTD. (COLINZ)?
The operating margin of COLINZ LABORATORIES LTD. is 1.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at COLINZ LABORATORIES LTD. (COLINZ)?
Revenue at COLINZ LABORATORIES LTD. is growing −20.8% versus a year earlier (3y avg −5.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at COLINZ LABORATORIES LTD. (COLINZ)?
Earnings per share at COLINZ LABORATORIES LTD. are growing +19.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does COLINZ LABORATORIES LTD. (COLINZ) carry?
The net debt of COLINZ LABORATORIES LTD. is ₹4.0M (fiscal year 2018, ≈ 0.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch COLINZ LABORATORIES LTD. in the live analysis
One click puts COLINZ LABORATORIES LTD. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
